During the past decade, Montefiore Einstein Center for Cancer Care conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 5 clinical trials were completed, i.e. on average, 21.7% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 3 clinical trials were completed. i.e. 18.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Montefiore Einstein Center for Cancer Care" #1 sponsor was "Pfizer" with 4 trials, followed by "Amgen" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Advanced Accelerator Applications" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Montefiore Einstein Center for Cancer Care" #1 collaborator was "ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Atridia Pty Ltd." with 1 trials as a collaborator, "Clinipace Worldwide" with 1 trials as a collaborator, "Dana-Farber Cancer Institute" with 1 trials as a collaborator and "Duke University" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Montefiore Einstein Center for Cancer Care" are "Multiple Myeloma" (2 trials), "Advanced Solid Tumor" (1 trials), "Advanced Solid Tumors" (1 trials), "Breast Cancer" (1 trials) and "Breast Cancer Female" (1 trials). Many other conditions were trialed in "Montefiore Einstein Center for Cancer Care" in a lesser frequency.

Most popular intervention types in "Montefiore Einstein Center for Cancer Care" are "Drug" (24 trials), "Biological" (3 trials), "Other" (2 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (2 trials), "Carboplatin" (2 trials), "Docetaxel" (2 trials), "Nab paclitaxel" (2 trials) and "Nivolumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Montefiore Einstein Center for Cancer Care" are 25 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Montefiore Einstein Center for Cancer Care". 1 are not yet recruiting, 14 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Montefiore Einstein Center for Cancer Care, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Montefiore Einstein Center for Cancer Care, 12 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".